The question of the nature of dark energy and dark matter is considered. It is extremely interesting that there is still no clear understanding of the nature of dark energy, as well as the extreme scarcity of information about dark matter. So what is this darkest energy?
TI1e cltloiamphenicol is D+threo (-) 2,2 dichloro-N--hydroxy -a( hydroxyl methyl)-pn.itropbenyl acetamide, a bacterioststic and highly effective antibacterial against gr(+) and gr (-) ocular patbogenic bacteria causing conjunctivitis or corn.ea] ulcers. The ophthalmi.c preparations of chloramphen.icol are produced in different formulation due to its lower stability . Therefore , the present study introduce the know-how for the production of cholramphenicol sterjle ophthalmic solution. The ophthalmic preparations of ch1oramphenicol 0.4% are not produced ir,i Syria as well as the actice agent. Therefore , the prepared report produces the know -bow for the production and study the stability for sterile solution. chloramphenicol for ophlha1mic solution is a sterile, dsy mixture with borax buffer .The active ingredient is chloramphenicol at concentration ( 40mg I ml ) was prepared under aseptic conditions. The fait yellow color ophthalmic so1ution , clear , sterile , isotonic with 306 mOsm / Kg , the pH measured at 6.51. This so1ution did not cause any eye irritation in rabbits after daily application for four consecutive days . Finally , tbe stability of the prepared chloramphenicol 0.4 % eye drops was studied at 4, 25 , 40 and 50C0 for 90 days in glass amber containers and calculated tl1e expiration date of the preparation on was approximately two years
Numerous drugs have the potential to be affected by cytochrome P450 (CYP) 2B6-mediated drug–drug interactions (DDIs). In this work, we extend a static approach to the prediction of the extent of pharmacokinetics DDIs between substrates and inhibitors or inducers of CYP2B6. This approach is based on the calculation of two parameters (the contribution ratio [CR], representing the fraction of dose of the substrate metabolized via this pathway and the inhibitory or inducing potency of the perpetrator [IR or IC, respectively]) calculated from the area under the concentration–time curve (AUC) ratios obtained in in-vivo DDI studies. Forty-eight studies involving 5 substrates, 11 inhibitors and 18 inducers of CYP2B6 (overall 15 inhibition and 33 induction studies) were divided into test and validation sets and considered for estimation of the parameters. The proposed approach demonstrated a fair accuracy for predicting the extent of DDI related to CYP2B6 inhibition and induction, all predictions related to the validation test (N = 18) being 50–200% of the observed ratios. This methodology can be used for proposing initial dose adaptations to be adopted, for example in clinical use or for designing DDI studies involving this enzyme.
AbstractAlzheimer’s disease (AD) biomarkers represent several neurodegenerative processes, such as synaptic dysfunction, neuronal inflammation and injury, as well as amyloid pathology. We performed an exome-wide rare variant analysis of six AD biomarkers (β-amyloid, total/phosphorylated tau, Nfl, YKL-40, and Neurogranin) to discover genes associated with these markers. Genetic and biomarker information was available for 480 participants from two studies: EMIF-AD and ADNI. We applied a principal component (PC) analysis to derive biomarkers combinations, which represent statistically independent biological processes. We then tested whether rare variants in 9,576 protein-coding genes associate with these PCs using a Meta-SKAT test. We also tested whether the PCs are intermediary to gene effects on AD symptoms with a SMUT test. One PC loaded on Nfl and YKL-40, indicators of neuronal injury and inflammation. Three genes were associated with this PC: IFFO1, DTNB and NLRC3. Mediation tests suggest, that these genes also affect dementia symptoms via inflammation/injury. We also observed an association between a PC loading on Neurogranin, a marker for synaptic functioning, with GABBR2 and CASZ1, but no mediation effects. The results suggest that rare variants in IFFO1, DTNB and NLRC3 heighten susceptibility to neuronal injury and inflammation, potentially by altering cytoskeleton structure and immune activity disinhibition, resulting in an elevated dementia risk. GABBR2 and CASZ1 were associated with synaptic functioning, but mediation analyses suggest that the effect of these two genes on synaptic functioning is not consequential for AD development.
